Voluntary Scheme for Branded Medicines Pricing and Access

(asked on 25th January 2023) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has received evidence from the life sciences industry of the impact on UK R&D investment and potential increases in payment rates under the voluntary and statutory schemes for branded medicines; and if it will make a statement.

Answered by
Will Quince Portrait
Will Quince
This question was answered on 1st February 2023

The Department has been consulting on a proposed update to the statutory scheme for branded medicines and the life sciences industry has been able to give evidence as part of this consultation process.

The Government remains firmly committed to the statutory and voluntary schemes for branded medicines and to working with the pharmaceutical industry to deliver on the ambitions set out in the Life Sciences Vision to create an environment that facilitates innovation for the development of medicines in the UK.

Reticulating Splines